By Rob Verkerk, PhD, ANH founder and ANH-USA executive and scientific director
This article is adapted from a longer personal account first published by ANH International.
Listen to the audio version of this article:
THE TOPLINE
- I developed a suspected serious hypersensitivity reaction within days of starting allopurinol ahead of foot surgery.
- My experience raises difficult questions about informed consent, individualized risk, baseline testing, dosing and monitoring.
- We do not need a war between conventional and natural medicine. We need connected healthcare that puts the person before the protocol.
For most of my adult life, I have lived almost entirely outside the pharmaceutical model—not because of ideology, but because of experience.
In my twenties, I was diagnosed with multiple chemical sensitivity following severe reactions to pesticides, solvents and pharmaceutical drugs. A particularly serious reaction to the antimalarial drug Lariam reinforced my caution. For more than 30 years after that, I avoided prescription medicines.
Then, earlier this year, that changed.
A Motorcycle Injury Comes Back to Haunt Me
In 1995, I badly damaged my right foot in a motorcycle accident in Malaysia. Decades later, increasingly painful inflammation was interfering with walking and cycling. Imaging showed a protective mass around the damaged bone, along with what appeared to be urate crystals.
An orthopedic surgeon agreed to remove the mass and remodel the bone, but first recommended six months of allopurinol—a standard uric-acid-lowering drug—even though I had never suffered from gout.
Busy with work and a house move, I deferred to the specialist and obtained the prescription. Six days after starting the drug, while driving, seemingly out of nowhere, extraordinary cramps spread across multiple muscle groups. The pain felt as though acid had been poured into my muscles. I stopped the drug, but the reaction did not stop.
Over the following days came worsening muscle pain, rashes, skin sensitivity, numbness and neuropathic symptoms affecting my arms, hands and one leg. At night, the pain became so intense I couldn’t sleep and the only relief I could get was by getting up and walking.
My research, subsequently supported by a medical center in France, pointed toward a serious hypersensitivity reaction. I discovered that full-blown allopurinol hypersensitivity syndrome is rare—estimated at around one in 1,000 users—but can carry a disturbingly high mortality rate of 20–25 percent.
With guidance from Nasha Winters, ND, a member of ANH-USA’s board, I pursued testing for possible effects on my kidneys, liver, muscles and nerves, while supporting recovery through rest, hydration, nutrition and targeted natural compounds. Thankfully, the symptoms are beginning to ease, with the neuropathic ones—especially numbness in the hands and left thigh—being the slowest to improve.
The Questions Every Patient Deserves to Have Answered
This experience left me asking:
- Why was my history of extreme sensitivity to drugs and chemicals not explored in detail by the orthopaedic surgeon?
- Why did I not feel properly informed about the possibility of a severe reaction?
- Why were these kinds of severe reactions nowhere to be seen on the patient information leaflet accompanying the prescription.
- Why was there so little interest in my wider biochemical, metabolic and nutritional terrain?
- Could baseline testing, lower starting doses, gradual titration or closer monitoring have reduced the risk?
These are not fringe questions. FDA-approved prescribing information warns that allopurinol can cause serious and sometimes fatal reactions. Yet allopurinol is the preferred first-line, standard-of-care medication for managing chronic gout in the United States, as recommended by the Arthritis Foundation. For gout patients, it calls for baseline assessment of uric acid, blood counts, liver chemistry and kidney function, and notes that lower initial doses with gradual titration can reduce serious adverse reactions.
Known Does Not Mean Normal
We have become far too accustomed to the phrase “side effect.” Television drug ads recite terrifying lists so routinely that they fade into background noise.
But a “side effect” can mean pain so severe you cannot sleep. It can mean being unable to walk comfortably or drive safely. It can mean wondering in the middle of the night whether something is going seriously wrong inside your body. A “side effect” may or may not include a hypersensitivity reaction—it depends who you ask.
A reaction does not become normal because it is listed in fine print. “Known” does not mean trivial—and it should never erase the obligation to consider susceptibility, alternatives and individual context.
Better Medicine Uses the Best of Both Worlds
Natural medicine cannot repair the structural damage in my foot. I still need a skilled surgeon. Modern imaging, laboratory medicine, emergency care and surgery are extraordinary achievements.
But imagine a system in which the surgeon was also deeply interested in the patient’s physiological, metabolic and nutritional terrain. Imagine conventional clinicians working routinely with professionals trained in nutritional, functional and natural medicine.
That would not be “alternative” medicine. It would simply be better medicine.
Patients must be partners, not passive recipients. Clinicians must see the individual before the protocol. And when suspected adverse reactions occur, they must enter the safety record. In the United States, patients and healthcare professionals can report them directly through FDA MedWatch. Clinicians are not required to file these reports, so patient reporting matters.
We do not need competing medical tribes. We need connected health systems that combine the safest and most appropriate tools available—from the operating room and diagnostic laboratory to the food we eat, the way we live and the natural world.
That is the future of healthcare I want to see—and the future ANH is working to create.
If you have suffered an adverse reaction to a drug or know someone who has, it is important to report the reaction. Find out how to do it via FDA’s MedWatch portal.
Please share this article widely so more patients recognize that informed consent and adverse event reporting are rights, not optional extras.
